Astrazeneca (AZN) Operating Leases (2019 - 2026)

Astrazeneca's Operating Leases history runs 8 years deep, the most recent figure standing at -$1.5 billion for Q1 2026.

• In Q1 2026, Operating Leases fell 25.84% year-over-year to -$1.5 billion; the TTM figure through Mar 2026 stood at -$1.5 billion (down 25.84% YoY), while the FY2025 annual figure was -$1.4 billion, down 227.67% from the prior year.
• Operating Leases was -$1.5 billion for Q1 2026 at Astrazeneca, down from -$1.4 billion in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $1.1 billion in Q4 2024 to a low of -$1.5 billion in Q1 2026.
• Historically, Operating Leases has averaged -$655.2 million across 5 years, with a median of -$744.0 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Operating Leases increased 29.87% in 2024, then tumbled 227.67% in 2025.
• A 5-year view of Operating Leases shows it stood at $953.0 million in 2022, then slipped by 10.07% to $857.0 million in 2023, then advanced by 29.87% to $1.1 billion in 2024, then sank by 227.67% to -$1.4 billion in 2025, then fell by 5.91% to -$1.5 billion in 2026.
• The last three Operating Leases figures came in at -$1.5 billion (Q1 2026), -$1.4 billion (Q4 2025), and -$1.4 billion (Q3 2025), per Business Quant data.